Interleukin-6 (IL-6) family cytokines act via gp130 in the osteoblast lineage to stimulate formation of osteoclasts (bone resorbing cells), activity of osteoblasts (bone forming cells) and to inhibit expression of the osteocyte protein, sclerostin. We report here that a profound reduction in trabecular bone mass occurs both when gp130 is deleted in the entire osteoblast lineage (Osx1Cre gp130 f/f) and when this deletion is restricted to osteocytes (DMP1Cre gp130 f/f). This was caused not by an alteration in osteoclastogenesis, but with a low level of bone formation specific to the trabecular compartment. In contrast, at the periosteal surface of the diaphysis, bone formation increased cortical diameter to maintain ultimate bone strength, despite a weak cortical bone matrix and reduced collagen type 1 production. We conclude that osteocytic gp130 signalling is required for normal trabecular bone mass and healthy cortical bone composition, suggesting that stimulating gp130 signalling in osteocytes could increase bone mass and strength.
(IL-6) family cytokines, including IL-6, interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1)
(1). Cytokine-specific knockout mouse models have established unique and necessary roles for each of these cytokines in physiological regulation of longitudinal growth, periosteal expansion and trabecular structure (2) (3) (4) (5) (6) (7) (8) (9) , as well as bone loss associated with inflammation (10) and estrogen deficiency (11) .
Although gp130 is ubiquitously expressed (1) , stimulation of osteoclast formation by IL-6, IL-11, LIF, CT-1, and OSM depends on the presence of osteoblasts in vitro (12, 13) and is mediated by increased osteoblast RANKL mRNA expression (12) (13) (14) (15) . Furthermore, stimulation of osteoclast formation by other agents such as IL-1, PTH and 1,25-dihydroxyvitamin D 3 , are also mediated, at least in part, by gp130 (3) . However, the role of osteoblast lineage gp130 signalling in osteoclast formation is not well defined, and has been complicated by conflicting effects on osteoclast formation by genetic deletion of individual cytokines that signal via gp130 and phenotypic differences between the sexes in vivo (1) . For example, systemic deletion of OSMR (6) inhibited osteoclast formation in male and female mice. A similar phenotype was reported in male mice with systemic deletion of IL-11R (16), but females showed only a reduction in osteoblastogenesis. In contrast, CT-1 knockout mice (9) had increased formation of osteoclasts with impaired activity in both males and females.
Further complicating the data, systemic LIF (5), LIFR (17) or gp130 deletion (18) resulted in increased numbers of large, active osteoclasts clustered near the growth plate in neonate mice.
The contrasting nature of these in vivo osteoclast phenotypes are remarkable, given the strong stimulatory effects of OSM, IL-6, CT-1 and IL-11 on osteoclast formation in vitro (13, 19) .
IL-6 family cytokines also act on the osteoblast lineage to stimulate bone formation. IL-6, IL-11, CT-1 and OSM all promote osteoblast differentiation in vitro (9, 20) , and OSM, CT-1, and LIF stimulate bone formation in vivo (6, 9, 21) . OSM, CT-1, LIF and IL-11 also inhibit adipocyte differentiation (5, 6, 9) , suggesting an influence of these cytokines on early osteoblast precursor commitment. Furthermore, OSM, CT-1, IL-11 and LIF influence terminally differentiated osteoblasts embedded within the bone matrix (osteocytes), by suppressing their production of sclerostin (6) , a potent inhibitor of Wnt signalling and bone formation (22) . This indicates that IL-6 family cytokines act on osteoblasts at all stages of differentiation (e.g. early osteoblasts, late osteoblasts, or osteocytes), but the relevant stages at which they support bone formation, bone resorption or adipogenesis are unknown (23) .
To determine the stage-specific roles of gp130 in the osteoblast lineage in both bone modelling and remodelling, we have generated two mouse models where gp130 was conditionally deleted either from the entire osteoblast lineage (Osx1Cre) or specifically in osteocytes (DMP1Cre). The data reported here indicate that gp130 signalling in the commited osteoblast lineage is not required for osteoclast differentiation in trabecular bone.
Rather, the key role of gp130 signalling in the osteoblast lineage is in osteocytes, where it maintains bone formation in trabecular bone and cortical bone strength. (26) . Mice hemizygous for the Cre transgene of each strain were crossed with a gp130 flox mouse in which the transmembrane domain (exon 15) was flanked by loxP sites, resulting in ablation of intracellular gp130 signalling, as previously reported (27) . For all experiments, appropriate Cre+ wildtype littermates or cousins were used as controls. Both male and female mice were analysed, as indicated below.
Materials and Methods

Animals
Samples for histomorphometry, microCT, RNA and serum analyses were collected at 6, 12 and 26 weeks of age, after injection with calcein at 3 and 10 days prior to tissue collection (28) . 12 week-old DMP1.gp130 and Osx1Cre.gp130 w/w and f/f mice (n=6/7 per genotype) were fasted for 12 hours prior to anesthesia with ketamine/xylazine and blood collection via cardiac puncture. Blood samples were centrifuged 10 minutes at 4,000 rpm and serum supernatant was removed to a fresh tube and stored at - DMP1Cre.gp130 f/f mice were harvested for RNA extraction as previously described (29) . and DMP1Cre.gp130 f/f mice via subcutaneous injection as previously described (9) . Calvaria were harvested upon sacrifice, 10 days after the last injection, and analysed by histomorphometry as previously described (9) .
Fluorescence activated cell sorting (FACS
Histomorphometry and microCT. Histomorphometry was performed on tibial sections as previously described (30) . Ex vivo microCT was performed on femoral, vertebral, and calvarial specimens using the SkyScan 1076 system (Bruker-microCT, Kontich, Belgium).
Images were acquired using the following settings: 9μm voxel resoluation, 0.5mm aluminum filter, 50kV voltage and 100μA current, exposure time, rotation 0.5 o , frame averaging =1.
Images were reconstructed and analysed using SkyScan software programs NRecon (version ), and energy (work) to failure (U; mJ) were calculated from the load-displacement curves as described previously (32) . The yield point was determined from the load deformation curve at the point at which the curve deviated from linear. Widths of the cortical mid-shaft in the medio-lateral (ML) and AP directions were measured using digital calipers, and the average cortical thickness was determined by microCT. Combining the geometric calculations and the biomechanical test results, the material properties of each bone were calculated as described by Schrieffer et al (33) to obtain ultimate stress (σ, MPa); elastic modulus (E, MPa), and modulus of toughness (u, MPa). Average load-deformation and stress-strain curves for each sex and genotype were also generated.
Reference Point Indentation. Local bone material properties at the femur mid-shafts from 12
week-old male DMP1Cre.gp130 mice (males n=5 w/w, n=9 f/f; females n=5 w/w, n=5 f/f)
were examined by reference point indentation using a BP2 probe assembly apparatus replicates were performed and averaged. All error bars are standard error of the mean (SEM).
Statistical significance was considered p<0.05. All statistics were calculated using unpaired Student's t-test or 1-way ANOVA (GraphPad software) or as indicated in the figure legends.
Results
Confirmation of deletion of functional gp130
Knockdown of gp130 was confirmed in FACS-sorted Osx1Cre-GFP-expressing neonate calvarial osteoblasts, which indicated a 70% reduction in gp130 expression in
Osx1Cre.gp130 f/f cells compared to controls (Fig. 1A) . Since the DMP1Cre construct does not contain a reporter element, gp130 knockdown of approximately 50% was verified in RNA from whole femurs, flushed of marrow, from both male and female 12-week old mice
To confirm deletion of functional response of gp130, DMP1Cre.gp130 f/f female mice and their controls were injected with OSM over the calvaria to stimulate bone formation (6).
While DMP1Cre.gp130 w/w mice formed additional bone in response to OSM, (Fig. 1C) . Furthermore, the increase in calvarial thickness and greater mineral apposition rate (MAR) in response to OSM in DMP1Cre.gp130 w/w mice was completely ablated by osteocytic deletion of gp130 (Fig. 1C) .
gp130 in the osteoblast lineage maintains trabecular bone volume
MicroCT analysis of trabecular bone structure revealed a significantly lower trabecular bone volume (BV/TV) and trabecular number (TbN) (Fig. 2A&C) , and significantly greater trabecular spacing (TbSp) in the femur ( Fig. 2D ) and vertebrae ( Fig. S1) 4D ) mice compared to controls, confirming reduced osteoblast differentiation in the absence of osteocyte gp130. To determine whether this was associated with diversion towards the adipocyte lineage, marrow adipocyte numbers were evaluated in Osx1Cre.gp130 f/f mice, and were at wildtype levels in both male and female 12 week-old mice (data not shown).
Despite the known influence of IL-6 family cytokines on osteoclastogenesis, osteoclast number (NOc/BPm), surface/bone surface (OcS/BS), and length (OcL) were not significantly different in DMP1Cre.gp130 f/f or Osx1Cre.gp130 f/f male or female mice compared to controls (Table 2) .
Cortical circumference is increased with gp130 deletion in the osteoblast lineage
The cortical bone phenotypes of DMP1Cre.gp130 12 and 26 week-old male mice (Fig. 5A) were strikingly different to those observed in trabecular bone. Although there was no change in bone length (Fig. S5) (Fig. 6A-C) , and elastic modulus was significantly lower in female DMP1Cre.gp130 f/f mice (Fig. 6A) . Toughness (amount of energy required to fracture the bone) was also slightly lower in the males, but this was not statistically significant ( Fig. 6D ). Parameters that are not corrected for the altered size and shape of the bone (stiffness, failure force, deformation at failure, and energy absorbed at failure) were not significantly different in DMP1Cre.gp130 f/f males or females compared to w/w controls ( Table 3 ), indicating that the structural integrity of the whole bone remained intact due to the increased cortical dimensions. The load-deformation graphs confirm no difference in response to mechanical load in either the male or female mice prior to normalization for bone geometry (Fig. 6E&F) . In contrast, the average stress-strain curves demonstrate that after normalization for bone geometry, the DMP1Cre.gp130 f/f male bones are more compliant and withstand less stress than their wildtype counterparts (Fig. 6G&H) . Post-yield stress was also significantly reduced in male DMP1Cre.gp130 f/f mice only ( Figure 6I ). Since the bones from the DMP1Cre.gp130 f/f males had poorer material properties, tissue mineral density was assessed by microCT on bones from 12 week-old mice (Fig. S6A) but no difference between w/w and f/f mice was detected.
To determine whether the poor matrix material properties were due to differences in the proportion of woven vs lamellar bone in DMP1Cre.gp130 f/f mice, 100μm transverse sections of 12 week-old male femora were analysed by polarized light microscopy. DMP1Cre.gp130
f/f mice showed a significantly higher proportion of disorganized woven bone compared to lamellar bone matrix in the proximal femur (Fig. 6J ).
When 12 week-old bones from these mice were analysed by reference point indentation (RPI), there was no difference in total indentation distance, average loading or unloading slopes, or indentation distance increase after loading (Fig. S6B) , suggesting that the poor material properties of DMP1Cre.gp130 f/f bones do not relate to a defect at the micro-indentation level.
Osteocyte density is greater in the trabecular compartment of gp130 osteocyte conditional knockout mice, resulting in greater local production of sclerostin
The trabecular compartment-specific reduction in bone formation rate in the absence of gp130 in osteocytes suggests that osteoblasts in the trabecular bone and periosteum respond differently to gp130 signals controlling bone formation. Since OSM, LIF, IL-11, and CT-1 all inhibit osteocyte production of the bone formation inhibitor sclerostin (6), the density of total osteocytes and sclerostin-positive osteocytes was assessed in 12 week-old male
Osx1Cre.gp130 and DMP1Cre.gp130 cortical and trabecular bone to determine whether region-specific changes in osteocyte number and sclerostin production could explain the region-specific phenotype. Osteocyte density was no different in the trabecular vs cortical bone of the Osx1Cre.gp130 f/f mice (Fig. 7A) . However, Osx1Cre.gp130 f/f mice had significantly more sclerostin-positive osteocytes in both trabecular and cortical bone than their w/w controls (Fig. 7B) , suggesting that gp130 deletion early in the osteoblast lineage increases the number of osteocytes that express sclerostin throughout trabecular and cortical bone.
In contrast to the Osx1Cre.gp130 f/f mice, there was no significant difference in total osteocyte density in trabecular bone between DMP1Cre.gp130 w/w and DMP1Cre.gp130 f/f mice.
However, within DMP1Cre.gp130 f/f mice, there was a substantially greater numerical density of osteocytes in the trabecular bone compared to the cortical bone of the same mice (Fig. 7A) . Since osteocyte sclerostin production was increased in both the trabecular and cortical bone, but only in Osx1Cre.gp130 f/f mice, these data also indicate that region-specific patterns of sclerostin production are not responsible for the region-specific phenotype observed in both
Osx1Cre.gp130 f/f and DMP1Cre.gp130 f/f mice.
Osteocyte deletion of gp130 reduces osterix, collagen type 1-α1, and osteocalcin gene expression
To assess the effects of gp130 deletion on gene expression in bone, we determined differences in osteoblast and osteocyte marker genes in flushed femurs of DMP1Cre.gp130
f/f mice with verified gp130 knockdown (Fig. 1B) . mRNA levels of the early osteoblast marker osterix (Fig. 8A ) and mature osteoblast marker osteocalcin (Fig. 8B) , as well as collagen type 1-α1 (Fig. 8C) , were all significantly lower (~50%) in bones from DMP1Cre.gp130 f/f mice compared to DMP1Cre.gp130 w/w mice. Notably, collagen type 1-α2 mRNA levels were not significantly changed in f/f bones (Fig. 8D) . Thus the ratio of collagen type 1-α1: collagen type 1-α2, which normally exists in a 2:1 ratio, was reduced (Fig. 8E) . Neither receptor activator of NF κ B ligand (RANKL; Tnfsf11) nor Sost mRNA levels were significantly different in DMP1Cre.gp130 f/f mice compared to controls (Fig. 8F) .
Discussion
This work demonstrates that the key cell through which gp130 controls trabecular bone formation and cortical bone strength is the osteocyte. Genetic deletion of gp130 in osteocytes results in very low trabecular bone formation rate and mass, and larger cortical bone diameter that compensates for significantly degraded cortical bone material properties and low collagen production. This regionally divergent phenotype was confirmed in a second model where gp130 was deleted in the entire osteoblast lineage. In neither model of gp130 deficiency was osteoclastogenesis altered. This leads us to conclude that the increased RANKL production in the osteoblast lineage that occurs in response to IL-6 family cytokines does not play a key role in physiological bone growth and remodeling, but it is the regulation of osteoblast differentiation and matrix production through the osteocyte that is the key role of gp130 in the osteoblast lineage (Fig. 9) .
The findings of a low level of trabecular bone formation and increased cortical dimensions
elicited by gp130 deletion in osteocytes is unique. It contrasts with osteocyte-specific knockouts of other pathways that stimulate bone formation (β-catenin, Pkd1 and IGF-1) which result in low bone mass in both cortical and trabecular bone due to reduced bone formation at both sites (37) (38) (39) . These data suggest that stimulating gp130 signaling in osteocytes may increase trabecular bone formation and trabecular bone mass, without increasing osteoclast formation, a phenomenon that could be exploited therapeutically.
All IL-6 family members, apart from those that signal through CNTF receptor (CNTFR), stimulate osteoclast differentiation (1). This influence has been understood for many years to depend on the ability of these cytokines to stimulate RANKL production by osteoblastlineage cells (12) (13) (14) (15) . This is supported by in vitro co-culture studies, where osteoclast formation in response to IL-6 family cytokines depended on the presence of osteoblasts (13, 19) , and osteoclast formation in response to other cytokines and hormones such as IL-1, CT-1 deletion, altered osteoclast formation levels were intrinsic to the hemopoietic lineage (9, 16) . Importantly, in all of these mouse knockout models, the IL-6 family cytokine was deleted systemically, and therefore it is unclear whether the effects on osteoclastogenesis in these mice was due to the absence of gp130 signalling in the osteoblast lineage. The data presented here indicate that osteoclast formation in physiological bone remodelling does not require gp130 signalling in the committed osteoblast lineage (Fig. 9A) , and this is the first instance in which the absence of gp130 signalling was restricted to the osteoblast lineage.
This supports the concept that RANKL expression induced by IL-6 family cytokinesin the osteoblast lineage may be most important in specific conditions of elevated osteoclast formation such as estrogen deficiency (11) or inflammatory arthritis (10) . In addition, during bone development and growth, control of osteoclast formation by the IL-6 family may be restricted to the growth plate, as observed in the neonate-lethal LIFR and gp130 null mice (17, 18) and adult LIF deficient mice (5) . In this region, gp130-dependent osteoclastogenesis may be more directly controlled by hypertrophic chondrocytes than by the osteoblast lineage (5). This is further supported by a lack of bone phenotype in neonate or 6 week-old
Osx1Cre.gp130 f/f mice, indicating that gp130 signaling in the osteoblast lineage is not required for normal bone development, but its key role is to maintain bone formation in the physiological process of bone remodelling in the adult skeleton.
The low level of trabecular bone formation, lower osteoblast number, and reduced osterix, type 1 collagen and osteocalcin mRNA levels in DMP1Cre.gp130 f/f bones confirms a critical role for osteocyte gp130 in promoting osteoblast differentiation (Fig. 9B ). This confirms a physiological role for gp130 cytokines that stimulate bone formation in vivo and modify osteocyte gp130 signalling, such as OSM, CT-1, and LIF (6, 9, 40) . This is further supported by the complete absence of an anabolic response to supra-calvarial injections of OSM in
DMP1Cre.gp130 f/f mice. This is also consistent with the known stimulatory effects of IL-6 family cytokines on bone formation (6, 41) , and low levels of trabecular bone formation previously reported in mice with global deletion of LIF, CT-1, OSMR, IL-11R (5,6,9,16).
Although IL-6 family members that stimulate bone formation also inhibit adipogenesis in vitro (5, 6, 9, 16) , no change in marrow adipogenesis was observed in the osteoblast or osteocyte specific knockouts (data not shown). This indicates that the anti-adipogenic action of IL-6 family cytokines is mediated by gp130 signalling in non-committed osteoblast precursors prior to osterix expression (Fig. 9A) .
Deletion of gp130 in osteocytes led to decreased intrinsic bone strength (i.e. ultimate stress)
in DMP1Cre.gp130 f/f mice and increased the diaphyseal dimensions such that ultimate bending load remained unchanged. This means that the fracture resistance of the bones was retained despite a significant reduction in their material properties. This mechanical maintenance was achieved by an increase in periosteal dimensions, hence increased moment of inertia, to compensate for the decline in bone material quality. The modest increase in trabecular thickness, detected only by microCT, may also reflect this compensatory mechanism. Alternatively, since this slight increase in trabecular thickness was specific for the DMP1Cre model, which suggests that gp130 signaling in the osteocyte may limit the thickness of new trabeculae formed at the growth plate, and this limiting effect is negated when gp130 signaling is deleted throughout the osteoblast lineage. Accordingly, the low trabecular BFR reported here and measured in the secondary spongiosa reflects a lower rate of bone remodeling, not trabecular formation at the growth plate. Furthermore, the reduced material properties of the cortical bone in osteocytic gp130 deficiency suggests that gp130 signalling in osteocytes may improve collagen deposition during the osteoid production phase, or mineral deposition during matrix maturation (Fig. 9B,C) . Since no significant alterations in tissue mineral density or periosteal MAR were detected in 12 week-old DMP1Cre.gp130
f/f mice, the poor material properties of the bone matrix likely reflect a defect in collagen deposition rather than altered mineralization. Indeed this was supported by our findings that the ratio of collagen 1 type α1 to type α2 mRNA levels was altered, and there was a higher proportion of woven bone in cortical samples of these mice. However, we cannot rule out an alteration in the distribution of mineral in the bones of DMP1Cre.gp130 f/f mice, particularly
given the lower osteocalcin mRNA levels.
Although the DMP1Cre. Increased periosteal circumference has not been observed in any global gp130 knockout mouse models. In fact, IL-6, IL-11R, CT-1, and OSMR knockout models each show reduced periosteal circumference (2, 3, 6, 9) . This suggests that maintenance of cortical bone strength by increased periosteal apposition depends on influences of IL-6 family cytokines on other cell types that stimulate increased activity of periosteal osteoblasts. The increased periosteal expansion in DMP1Cre.gp130 f/f mice is likely to be a response to altered mechanical loading resulting from the poor material integrity. We were unable to detect an increase in periosteal bone formation on transverse and coronal sections at any single time point, which suggests that the periosteal expansion in these bones occurred slowly and over a long period of time, which may be indicative of a cumulative mechanical response over the life of the mouse.
This may also indicate that, even though OSM, OSMR and IL-11 mRNA levels in bone are increased in response to mechanical load (43) , periosteal bone formation that is likely induced by mechanical forces may not require gp130 signalling in osteocytes (Fig. 9D ).
More sclerostin-positive osteocytes were observed in both trabecular and cortical bone of The greater osteocyte density and low bone formation rate found specifically within the trabecular bone of the DMP1Cre.gp130 f/f mice is consistent with reports in human bone, where trabecular osteocyte density and bone formation rate were negatively correlated (44) .
This suggests that IL-6 family cytokines, in addition to reducing sclerostin (6), may also determine the rate at which osteocytes become incorporated within the trabecular network. It is also possible that in the absence of osteocytic gp130 osteoblast apoptosis is impaired, and more osteoblasts survive through to osteocyte differentiation, consistent with previous in vitro reports of an anti-apoptotic role of IL-6 family cytokines (45) . However, it remains unclear why this was observed only in DMP1Cre.gp130 f/f bones when the Osx1Cre.gp130
f/f mice also exhibited low trabecular bone mass.
Therapeutic use of IL-6 inhibition for inflammation is widespread (46) , and new IL-6 family inhibitors are actively being pursued for a wide range of disorders (47) . Clinical trials have begun to test the efficacy of a soluble form of gp130 (sgp130-Fc) that selectively blocks IL-6
trans-signalling by sequestering the IL-6:sIL-6R complex and preventing it from binding membrane-bound IL-6R (48, 49) . These pathologic conditions already exhibit increased fracture risk, and our findings of detrimental effects of osteocyte gp130 inhibition on trabecular bone mass and cortical bone material properties, indicates careful skeletal monitoring of patients enrolled in future clinical trials is warranted.
In conclusion, we report here an essential role for osteocyte gp130 signalling to support trabecular bone formation and healthy composition of the cortical bone matrix. These data also suggest that stimulation of gp130 signalling targeted to the osteocyte may provide therapeutic benefit by stimulating trabecular bone formation and preserving material properties in the cortical bone.
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